Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Richard F. Pops

CEORichard F. Pops

Employees

2,050

Employees2,050

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,050

Employees2,050

ALKS Key Statistics

Market cap

7.03B

Market cap7.03B

Price-Earnings ratio

46.90

Price-Earnings ratio46.90

Dividend yield

—

Dividend yield—

Average volume

2.00M

Average volume2.00M

High today

$42.83

High today$42.83

Low today

$39.64

Low today$39.64

Open price

$40.00

Open price$40.00

Volume

4.21M

Volume4.21M

52 Week high

$42.83

52 Week high$42.83

52 Week low

$25.17

52 Week low$25.17

Stock Snapshot

Alkermes(ALKS) stock is priced at $42.19, giving the company a market capitalization of 7.03B. It carries a P/E multiple of 46.90.

As of 2026-05-31, Alkermes(ALKS) stock has fluctuated between $39.64 and $42.83. The current price stands at $42.19, placing the stock +6.4% above today's low and -1.5% off the high.

Alkermes(ALKS) shares are trading with a volume of 4.21M, against a daily average of 2M.

During the past year, Alkermes(ALKS) stock moved between $25.17 at its lowest and $42.83 at its peak.

ALKS News

TipRanks 2d

Alkermes Insider Makes Major Move in Latest Stock Transaction

New insider activity at Alkermes ( (ALKS) ) has taken place on May 29, 2026. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ra...

Simply Wall St 3d

Assessing Alkermes Valuation After New Clinical And Real World Data On Key Psychiatry Drugs

Alkermes (NasdaqGS:ALKS) has drawn fresh attention after presenting new clinical and real world data on LYBALVI and ARISTADA at major psychiatry and health econ...

TipRanks 3d

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target

Ami Fadia, an analyst from Needham, maintained the Buy rating on Alkermes. The associated price target remains the same with $50.00. Unlock trusted, data-backe...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

18.8%

Sell

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.